Format

Send to

Choose Destination
Trends Immunol. 2014 Apr;35(4):178-85. doi: 10.1016/j.it.2014.02.003. Epub 2014 Mar 21.

Reprogramming antitumor immunity.

Author information

1
National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA; Department of Medicine, University of Cambridge School of Clinical Medicine, Cambridge CB2 2QH, UK; Department of Surgery, University of California Los Angeles, Los Angeles, CA 90095, USA.
2
National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA; Department of Medicine, University of Cambridge School of Clinical Medicine, Cambridge CB2 2QH, UK.
3
National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA.
4
Center for Regenerative Medicine, National Institutes of Health, NIH, Bethesda, MD 20892, USA.
5
National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA; Center for Regenerative Medicine, National Institutes of Health, NIH, Bethesda, MD 20892, USA. Electronic address: restifo@nih.gov.

Abstract

Regenerative medicine holds great promise in replacing tissues and organs lost to degenerative disease and injury. Application of the principles of cellular reprogramming for the treatment of cancer, however, is not well established. Here, we present an overview of cellular reprogramming techniques used in regenerative medicine, and within this context, envision how the scope of regenerative medicine may be expanded to treat metastatic cancer by revitalizing an exhausted and senescent immune system.

KEYWORDS:

T cell reprogramming; cancer immunotherapy; regenerative medicine

PMID:
24661777
PMCID:
PMC4373650
DOI:
10.1016/j.it.2014.02.003
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Elsevier Science Icon for PubMed Central
Loading ...
Support Center